Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Daniel Clair Added: 1 year ago
ISET 2025 - Safety and efficacy outcomes of an intravascular lithotripsy (IVL) catheter used for the treatment of moderate to severely calcified lesions show a high ability to deliver the catheter with access to the lesion and very low rates of myocardial infarction and distal embolisation.Dr Daniel Clair (Vanderbilt University Medical Center, TN, US) joins us to discuss the key findings from the… View more
Added: 11 months ago
Interventional Cardiology 2025;20:e22 View more
Author(s): Oliver Schlager Added: 9 months ago
ESC Congress 2025 - New guidelines for catheter-based VTE therapy emphasise the importance of involving vascular experts, and performing procedures in experienced centers.Dr Oliver Schlager (Medical University of Vienna, AT) joins us to discuss the newly released 2025 ESVM Guidelines on Interventional Treatment of Venous Thromboembolism, endorsed by European national societies of Vascular… View more
Author(s): Catalin Toma Added: 1 week ago
Dr Catalin Toma joins us to share practical guidance on catheter-based intervention for pulmonary embolism, offering clinical insights for interventionalists navigating this increasingly active space.As catheter-directed therapies for PE continue to evolve and expand into more centres, questions around patient selection, technique, and post-procedural management remain front of mind for the… View more
Author(s): Nicolas M Van Mieghem Added: 1 month ago
In this EuroPCR 2026 preview, Prof Nicolas Van Mieghem (Erasmus University, NL) walks through the most anticipated late-breaking trials across calcified coronary disease, structural heart intervention, and mechanical support — from laser-based IVL and atherectomy comparisons to three-year TAVI outcomes, tricuspid repair, high-risk PCI, and pulmonary embolism therapy.Editor: Mirjam Boros View more
Dr David Conen is a cardiologist, scientist and principal investigator at the Population Health Institute at McMaster University in Hamilton, Canada. Dr Conen is Principal Investigator of two major international trials studying the treatment and prevention of atrial fibrillation – the COP-AF and ASPIRE-AF Trials. View more